NeuroSense Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
NeuroSense Therapeutics has a total shareholder equity of $2.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.6M and $2.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.38m |
| Equity | US$2.58m |
| Total liabilities | US$1.99m |
| Total assets | US$4.58m |
Recent financial health updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22
Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Recent updates
NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely
Mar 22Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?
Dec 06Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Mar 03Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?
Nov 17NeuroSense Therapeutics GAAP EPS of -$0.55
Aug 31We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
Jul 06NeuroSense climbs 66% after early data supporting Alzheimer’s candidate
Jun 30Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?
Mar 31NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans
Mar 22NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Dec 22Financial Position Analysis
Short Term Liabilities: NRSN's short term assets ($4.4M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: NRSN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NRSN is debt free.
Reducing Debt: NRSN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NRSN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NRSN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 45% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 19:34 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroSense Therapeutics Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Jason Kolbert | D. Boral Capital LLC. |
| Nazibur Rahman | Maxim Group |